scholarly journals Effects of Electrical Muscle Stimulation Against Acute Adverse Effect and Cancer Cachexia During Non-small Cell Lung Cancer Chemo-Radiotherapy

2018 ◽  
Vol 64 (Suppl.1) ◽  
pp. 160-160
Author(s):  
ANNEYUKO I SAITO ◽  
TOSHIHARU NATSUME ◽  
TATSUYA INOUE ◽  
KEISUKE SASAI ◽  
HISASHI NAITO
Keyword(s):  
Lung Cancer ◽  
Adverse Effect ◽  
Small Cell Lung Cancer ◽  
Cancer Cachexia ◽  
Small Cell ◽  
Muscle Stimulation ◽  
Electrical Muscle Stimulation ◽  
Small Cell Lung ◽  
Acute Adverse Effect ◽  
Electrical Muscle

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2006 ◽  
Vol 24 (16) ◽  
pp. 2549-2556 ◽  
Author(s):  
Masahiko Ando ◽  
Isamu Okamoto ◽  
Nobuyuki Yamamoto ◽  
Koji Takeda ◽  
Kenji Tamura ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Adverse Effect ◽  
Interstitial Lung Disease ◽  
Small Cell Lung Cancer ◽  
Predictive Factors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Antitumor Response ◽  
History Of

Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence and risk factors remain largely unknown. We examined the prevalence of and risk factors for gefitinib-induced ILD associated with practical use of the drug in Japanese with non–small-cell lung cancer (NSCLC). Patients and Methods Clinical information was retrospectively assembled for NSCLC patients who started gefitinib treatment at affiliated institutions of the West Japan Thoracic Oncology Group between August 31 and December 31, 2002. Medical records of patients who developed pulmonary infiltrates were reviewed by a central committee of extramural experts for identification of patients with gefitinib-induced ILD. Multivariate logistic or Cox regression analysis was performed to identify independent predictive factors for ILD, antitumor response, and survival. Results Seventy cases of and 31 deaths from gefitinib-induced ILD were identified among 1,976 consecutively treated patients at 84 institutions, corresponding to a prevalence of 3.5% and mortality of 1.6%. Gefitinib-induced ILD was significantly associated with male sex, a history of smoking, and coincidence of interstitial pneumonia (odds ratios = 3.10, 4.79, and 2.89, respectively). Predictive factors for response were female sex, no history of smoking, adenocarcinoma histology, metastatic disease, and good performance status (PS), whereas predictive factors for survival were female sex, no history of smoking, adenocarcinoma histology, nonmetastatic disease, good PS, and previous chest surgery. Conclusion ILD is a serious adverse effect of gefitinib in the clinical setting that cannot be ignored. However, patient selection based on sex and smoking history can minimize ILD risk and maximize the clinical benefit of gefitinib.

Impact of Cancer Cachexia on Treatment With PD-1/PD-L1 Inhibitors Plus Chemotherapy in Advanced Non-small-Cell Lung Cancer

2021 ◽  
Author(s):  
Taichi Miyawaki ◽  
Tateaki Naito ◽  
Michitoshi Yabe ◽  
Hiroaki Kodama ◽  
Naoya Nishioka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cancer Cachexia ◽  
Advanced Nsclc ◽  
Group Performance ◽  
Objective Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Impact

Abstract PurposeProgrammed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors plus chemotherapy has become the standard first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC). However, few studies have explicitly focused on the impact of cancer cachexia on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy. Thus, we evaluated the clinical implications of cancer cachexia on the survival outcomes in patients who received this treatment.MethodsWe conducted a retrospective review of medical records of patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors plus chemotherapy from December 2018 to December 2020. Cancer cachexia was diagnosed as an unintentional weight loss of 5% or more over six months. We evaluated the progression-free survival (PFS) and overall survival (OS) for patients with or without cancer cachexia who received PD-1/PD-L1 inhibitors plus chemotherapy.ResultsAmong the 80 included patients, 37 (46%) had cancer cachexia. Cachectic patients had a lower objective response rate (30 vs 51%, P <0.05), poorer PFS (2.3 vs 12.0 months, P <0.05), and poorer OS (10.8 vs 23.9 months, P <0.05) than non-cachectic patients. The Cox proportional-hazard ratios (95% confidence interval) of cancer cachexia were 1.77 (1.01–3.10) for PFS and 2.90 (1.40–6.00) for OS, with adjustments for Eastern Cooperative Oncology Group performance status, PD-L1 tumour proportion score, histology, and central nervous system metastases. ConclusionPre-treatment cancer cachexia may reduce treatment efficacy and shorten survival time in patients receiving PD-1/PD-L1 inhibitors plus chemotherapy. Early evaluation and intervention for cancer cachexia might improve oncological outcomes in patients with advanced NSCLC.

Impact of socioeconomic status on pretreatment cachexia and survival in non-small cell lung cancer.

2017 ◽  
Vol 35 (31_suppl) ◽  
pp. 101-101
Author(s):  
Steven Lau ◽  
Bhavani S Gannavarapu ◽  
Kristen Carter ◽  
Ang Gao ◽  
Chul Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Socioeconomic Status ◽  
Educational Attainment ◽  
Small Cell Lung Cancer ◽  
Household Income ◽  
Cancer Cachexia ◽  
Small Cell ◽  
Insurance Status ◽  
Small Cell Lung ◽  
Pre Treatment

101 Background: Socioeconomic status (SES) influences healthcare outcomes, but the influence of SES on cancer cachexia is unknown. We identify components of SES associated with pre-treatment cachexia in patients with non-small cell lung cancer (NSCLC) and assess their prognostic significance on survival. Methods: A prospectively maintained institutional tumor registry identified 1,365 patients with NSCLC consecutively treated at a tertiary care health system from 1/1/06 to 12/31/13. Insurance status was abstracted from the registry. Educational attainment and household income were estimated from census data using location of primary residence. Cancer cachexia was defined retrospectively using the international consensus definition. Multivariable regression analysis was used to identify prognostic factors of pre-treatment cancer cachexia and survival. Results: Cachexia was present at the time of NSCLC diagnosis in 30% of all patients including 17% of patients with stage I disease. Patients with Medicaid or no insurance were more likely to have pre-treatment cachexia compared to those with private insurance (Odds Ratio [OR] 1.9, 95% Confidence Interval [CI] 1.2-3.1; OR 2.1, 95% CI 1.2-3.4, respectively). Attainment of a high school diploma was inversely associated with pre-treatment cachexia (OR: 0.1, 95% CI 0.02-0.2). On multivariable analysis, comorbidity, histology, tumor grade, and disease stage were prognostic of survival among cachectic patients; however, insurance status, educational attainment, and household income were not. Conclusions: Lower SES is associated with pre-treatment cachexia in patients with NSCLC, but pre-treatment cachexia is detrimental to survival regardless of SES. Together, these findings suggest early intervention for patients with cancer cachexia may improve outcomes.

scholarly journals Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia

2015 ◽  
Vol 6 (2) ◽  
pp. 164-173 ◽  
Author(s):  
Celine M. Op den Kamp ◽  
Harry R. Gosker ◽  
Suzanne Lagarde ◽  
Daniel Y. Tan ◽  
Frank J. Snepvangers ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cancer Cachexia ◽  
Small Cell ◽  
Metabolic Phenotype ◽  
Newly Diagnosed ◽  
Small Cell Lung

scholarly journals Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non–Small-Cell Lung Cancer

2018 ◽  
Vol 14 (4) ◽  
pp. e211-e220 ◽  
Author(s):  
Steven K.M. Lau ◽  
Bhavani S. Gannavarapu ◽  
Kristen Carter ◽  
Ang Gao ◽  
Chul Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Socioeconomic Status ◽  
Weight Loss ◽  
Small Cell Lung Cancer ◽  
Odds Ratio ◽  
Cancer Cachexia ◽  
Small Cell ◽  
Disease Stage ◽  
Small Cell Lung ◽  
Primary Payer

Purpose: Socioeconomic status (SES) influences health care outcomes, but the influence of primary payer on cancer-associated wasting is unknown. We hypothesized that primary payer as an indicator of SES would influence pretreatment cancer-associated weight loss and treatment outcomes. Materials and Methods: Retrospective review of medical records identified 1,366 patients with non–small-cell lung cancer (NSCLC) consecutively treated at a tertiary care health system between January 1, 2006 and December 31, 2013. Insurance status was obtained from an institutional tumor registry. Cancer-associated weight loss was based on the validated international consensus definition of cachexia. Multivariable regression analyses were used to identify prognostic factors of pretreatment cancer-associated weight loss and survival. Results: The cohort included a representative group of patients with a median age at diagnosis of 64 years, 47% females, and 33% patients of nonwhite race. Pretreatment cancer-associated weight loss was present at the time of NSCLC diagnosis in 17%, 14%, 32%, and 38% of patients with stage I, II, III, and IV disease, respectively. Pretreatment cancer-associated weight loss was associated with increasing age at diagnosis, black race, single marital status, tobacco use, and disease stage. Compared with private insurance, Medicaid insurance (odds ratio, 2.17; 95% CI, 1.42 to 3.30) and lack of insurance (odds ratio, 2.32; 95% CI, 1.50 to 3.58) were associated with pretreatment cancer-associated weight loss. Among cachectic patients, comorbidity, histology, tumor grade, and disease stage were prognostic of survival on multivariable analysis; however, primary payer was not. Conclusion: Pretreatment cancer-associated weight loss is common in patients with NSCLC, and its presence is significantly associated with lower SES. However, among patients with pretreatment cancer-associated weight loss, SES was not predictive of survival. Early use of cancer cachexia–directed therapies may improve outcomes, and further study on the biologic mechanisms of cancer cachexia will provide novel therapeutic avenues.

Sign in / Sign up

Export Citation Format

Share Document